Nectar Lifesciences share news, announcements and annual reports
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Nectar Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2005
Last close ₹10.20down ₹0.13 (1.26%)BSE ₹10.29
Share price at the NSE close on 30 Oct 2026. Previous close ₹10.33.
30 Oct: open ₹10.43, high ₹10.43, low ₹9.82
52-week range of traded prices to 30 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹198 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 95,05079.2% delivered
Nectar Lifesciences results
73 filed, newest first. Page 2 of 2.
Feb 2015
13 Feb · Results
Nov 2014
12 Nov · Results
Aug 2014
11 Aug · Results
May 2014
28 May · Results
Feb 2014
11 Feb · Results
Nov 2013
13 Nov · Results
Aug 2013
13 Aug · Results
May 2013
15 May · Results
Feb 2013
Nov 2012
Aug 2012
May 2012
14 May · Results
Feb 2012
Nov 2011
Aug 2011
12 Aug · Results
May 2011
12 May · Results
Jan 2011
Nov 2010
May 2010
5 May · Results
The Company has opted to adopt the Audited Financial Results for the financial year ended 31 March, 2010 within a period of 60 days from the end of the last quarter of the relevant financial year. The Company will therefore, not publish the un-audited quarterly results of the quarter ending March 31, 2010
Apr 2009
21 Apr · Results
The Company would submit and publish the Audited Financial Results for the financial year ended March 31, 2009 on or before June 30, 2009, that is, within a period of 3 months from the end of the last quarter of the relevant financial year. The Company will therefore, not publish the un-audited quarterly results for the quarter ending March 31, 2009